BioScrip (BIOS) Upgraded to “Sell” by BidaskClub

BidaskClub upgraded shares of BioScrip (NASDAQ:BIOS) from a strong sell rating to a sell rating in a report released on Friday morning.

Several other research firms have also recently issued reports on BIOS. Canaccord Genuity assumed coverage on BioScrip in a research report on Wednesday, December 12th. They set a buy rating and a $5.00 target price for the company. TheStreet upgraded BioScrip from a d+ rating to a c- rating in a research report on Monday, November 26th. Lake Street Capital increased their target price on BioScrip from $4.50 to $10.00 and gave the stock a buy rating in a research report on Friday, December 7th. Finally, Zacks Investment Research cut BioScrip from a hold rating to a sell rating in a research report on Thursday, January 3rd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of $4.70.

NASDAQ BIOS opened at $2.34 on Friday. BioScrip has a 52 week low of $2.29 and a 52 week high of $4.14. The stock has a market capitalization of $355.95 million, a PE ratio of -5.32 and a beta of 0.76.

BioScrip (NASDAQ:BIOS) last released its earnings results on Friday, March 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.11). The company had revenue of $183.57 million during the quarter, compared to analysts’ expectations of $188.39 million. During the same period in the prior year, the company earned ($0.03) EPS. The company’s quarterly revenue was up .5% compared to the same quarter last year. On average, research analysts expect that BioScrip will post -0.34 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. Maven Securities LTD purchased a new position in BioScrip during the 4th quarter valued at approximately $45,000. Caxton Associates LP purchased a new position in BioScrip during the 4th quarter valued at approximately $52,000. Virtu Financial LLC grew its holdings in BioScrip by 60.6% during the 4th quarter. Virtu Financial LLC now owns 18,208 shares of the company’s stock valued at $65,000 after buying an additional 6,868 shares in the last quarter. Menta Capital LLC purchased a new position in BioScrip during the 4th quarter valued at approximately $124,000. Finally, Metropolitan Life Insurance Co. NY grew its holdings in BioScrip by 383.3% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 45,013 shares of the company’s stock valued at $161,000 after buying an additional 35,700 shares in the last quarter. Hedge funds and other institutional investors own 82.61% of the company’s stock.

About BioScrip

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Recommended Story: How Buying a Call Option Works

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.